Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 3Lung Neoplasms 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Vulvar Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Gallbladder Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1Adenocarcinoma 1

Interventions

atezolizumab 1Ritonavir 1Radiotherapy 1Oxaliplatin 1Indinavir 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × atezolizumab × Endocrine × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡